Biomerica, Inc. (NASDAQ:BMRA) Short Interest Down 15.7% in February

Biomerica, Inc. (NASDAQ:BMRA) saw a large drop in short interest during the month of February. As of February 27th, there was short interest totaling 60,973 shares, a drop of 15.7% from the February 12th total of 72,362 shares. Based on an average daily volume of 15,903 shares, the short-interest ratio is presently 3.8 days. Currently, 2.5% of the shares of the company are sold short. Currently, 2.5% of the shares of the company are sold short. Based on an average daily volume of 15,903 shares, the short-interest ratio is presently 3.8 days.

Institutional Investors Weigh In On Biomerica

A hedge fund recently raised its stake in Biomerica stock. DRW Securities LLC raised its holdings in shares of Biomerica, Inc. (NASDAQ:BMRA) by 62.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,925 shares of the company’s stock after acquiring an additional 6,533 shares during the quarter. DRW Securities LLC owned about 0.56% of Biomerica worth $43,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 22.28% of the company’s stock.

Biomerica Trading Up 4.0%

Biomerica stock opened at $2.08 on Wednesday. Biomerica has a 12 month low of $1.87 and a 12 month high of $5.92. The business’s 50 day simple moving average is $2.31 and its 200 day simple moving average is $2.54. The company has a market cap of $6.28 million, a price-to-earnings ratio of -2.24 and a beta of 0.21.

Biomerica (NASDAQ:BMRA) last released its earnings results on Wednesday, January 14th. The company reported ($0.45) earnings per share (EPS) for the quarter. The firm had revenue of $1.21 million during the quarter. Biomerica had a negative return on equity of 83.73% and a negative net margin of 90.29%.

Biomerica Company Profile

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.